Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Down 23.0% in December

Delcath Systems, Inc. (NASDAQ:DCTH) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 15th total of 1,350,000 shares. Based on an average daily volume of 386,900 shares, the short-interest ratio is presently 2.7 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. Polar Asset Management Partners Inc. bought a new stake in Delcath Systems during the 3rd quarter worth approximately $1,594,000. Shellback Capital LP acquired a new position in shares of Delcath Systems in the second quarter valued at approximately $1,353,000. Principal Financial Group Inc. bought a new stake in shares of Delcath Systems during the third quarter worth $808,000. Renaissance Technologies LLC acquired a new stake in shares of Delcath Systems during the second quarter worth $694,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Delcath Systems in the 2nd quarter valued at $370,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Stock Up 4.7 %

DCTH opened at $14.31 on Friday. The stock has a market cap of $457.55 million, a P/E ratio of -10.60 and a beta of 0.87. Delcath Systems has a 12 month low of $3.70 and a 12 month high of $14.47. The company has a fifty day simple moving average of $11.42 and a 200 day simple moving average of $9.88.

Analyst Ratings Changes

Several brokerages have recently commented on DCTH. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. Craig Hallum raised their price target on Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. Finally, StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and a consensus price target of $22.25.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.